Patient data analysis reveals that CDKN1A/p21 shows a notable preference for Luminal A type (Figure 3a) and HR (Hormone Receptor) subtypes following cancer patient stratification, which could hold significant implications for treatment options (Figure 3b). Here, CDKN1A is linked to cancer.